Filing Flows › Bolt Biotherapeutics (BOLT) › Q1 2026
Bolt Biotherapeutics (BOLT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Bolt Biotherapeutics (BOLT) reported revenue of $26K for the first quarter 2026 (Q1 2026), -98% from a year earlier and -99% from the quarter before.
Bolt Biotherapeutics, Q1 2026: revenue $26K (-98% year over year), net loss $7.2M, operating cash flow −$8.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26K | -99% | -98% |
| Operating profit | −$7.6M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$8.0M | — | — |
What changed
Revenue was $26K in Q1 2026, down 98% year over year and down 99% from the previous quarter.
Operating costs exceeded revenue by $7.6M, an operating margin of -29234.6%. Total costs fell 43% while revenue fell 98%. The quarter ended with a net loss of $7.2M, wider than the previous quarter's $6.6M loss.
Operating cash flow was −$8.0M. Non-cash charges added back $203K of depreciation and amortization and $545K of share-based compensation. Working capital and other items used $1.5M.
Questions
What was Bolt Biotherapeutics' revenue in the first quarter 2026?
Bolt Biotherapeutics (BOLT) reported revenue of $26K for the first quarter 2026 (Q1 2026), -98% from a year earlier and -99% from the quarter before.